Page last updated: 2024-08-21

isoxazoles and Neoplasms

isoxazoles has been researched along with Neoplasms in 63 studies

Research

Studies (63)

Timeframe	Studies, this research(%)	All Research%
pre-1990	7 (11.11)	18.7374
1990's	6 (9.52)	18.2507
2000's	8 (12.70)	29.6817
2010's	35 (55.56)	24.3611
2020's	7 (11.11)	2.80

Authors

Authors	Studies
Fang, X; Feng, J; Luan, Y; Wang, K	1
Guzhova, I; Margulis, B; Mikhaylova, E; Multhoff, G; Shevtsov, M; Shibata, A	1
Alexander, M; Dines-Muntaner, S; Fullerton, S; Thakerar, A; Trifunovich, T	1
Angeli, A; Carradori, S; Cirilli, R; D'Ascenzio, M; Guglielmi, P; Pierini, M; Poli, G; Secci, D; Supuran, CT; Tuccinardi, T; Zara, S	1
Andrs, M; Gorecki, L; Korabecny, J; Rezacova, M	1
Conlon, IL; Drennen, B; Fletcher, S; Hughes, S; Lanning, ME; MacKerell, AD; Rothhaas, R; Wilder, PT	1
Aoshiba, K; Kawagoe, J; Kikuchi, R; Koyama, N; Maeda, Y; Nakamura, H; Tsuji, T; Yamaguchi, K	1
Falk, M; Hendriks, BS; Jansen, M; Terranova, N	1
Benites, J; Buc Calderon, P; Muccioli, GG; Ramos, M; Valderrama, JA	1
Chen, Z; Li, L; Li, S; Yang, Y; Zhang, L	1
Chu, M; Zhang, C	1
Cheng, C; Jia, Y; Jin, X; Liu, Y; Wang, G; Yao, L; Zhang, J; Zhou, F	1
Chen, Y; Lin, HZ; Mo, J; Sun, HP; Zhu, J	1
Fernandez-Capetillo, O; Lecona, E	1
Behera, M; Hota, PK; Kotla, SR; Kumar, PR; Penugurti, V; Raghavulu, K; Shree, AJ; Velatooru, LR; Yennam, S	1
Akimov, M; Bailey, S; Banerji, U; Bhalla, KN; Britten, C; Chica, S; Fernandez-Ibarra, C; Jacks, KS; Lu, H; Mita, M; Papadimitrakopoulou, V; Pluard, T; Quadt, C; Samuel, TA; Sessa, C; Shapiro, GI	1
Ge, D; Lambrechts, MJ; Li, Q; Liu, S; Xi, M; Yin, R; You, Z; Zhang, Q	1
Bartzatt, R	1
Kloog, Y; Rak, R	1
Ding, Y; Shen, Q; Wild, C; Ye, N; Zhou, J	1
Astin, JW; Chien, A; Crosier, KE; Crosier, PS; Eng, TC; Flores, MV; Jamieson, SM; Misa, JP	1
Akimov, M; Boku, N; Doi, T; Fuse, N; Ohtsu, A; Onozawa, Y; Robson, M; Watanabe, J; Yamazaki, K; Yoshino, T	1
Bayer, C; Konrad, S; Kühnel, A; Multhoff, G; Schilling, D; Tetzlaff, F; Yaglom, J	1
Badr, JM; Khedr, A; Shaala, LA; Sulaiman, M; Youssef, DT	1
Foote, KM; Lau, A; Nissink, JW	1
An, H; Beauchamp, RD; Deane, NG; Lindsley, CW; Stoops, SL; Waterson, AG; Weaver, C; Zhu, J; Zi, J; Zijlstra, A	1
Bendell, JC; Earwood, C; Hart, L; Infante, JR; Jones, SF; Lane, CM; Moyhuddin, A; Murphy, P; Pant, S; Patton, J; Penley, WC; Thompson, D	1
Kim, ND; Lee, KB; Nam, Y; Shin, I; Sim, T; Yoon, H	1
Murali, K; Rajendra Prasad, KJ; Sparkes, HA	1
Bansal, N; Bertino, JR; Birge, RB; Comollo, T; Kholodovych, V; Kimani, SG; Kotenko, SV; Kumar, S; Peng, Y; Sarafianos, SG; Singh, K; Welsh, WJ	1
Bergström, M; Blomqvist, C; Ide, S; Josephsson, R; Langström, B; Monazzam, A; Razifar, P; Rugaard Jensen, M	1
de Jong, JR; de Korte, MA; de Vries, EG; den Dunnen, WF; Garcia-Echeverria, C; Hollema, H; Jensen, MR; Lub-de Hooge, MN; Nagengast, WB; Oude Munnink, TH; Quadt, C; Schröder, CP; Timmer-Bosscha, H; van Dongen, GA	1
Barraja, P; Carbone, A; Cirrincione, G; Diana, P; Fiebig, HH; Kelter, G	1
Chatterjee, M; Djuzenova, CS; Flentje, M; Jensen, MR; Stingl, L; Stühmer, T	1
Perrone, MG; Scilimati, A; Simone, L; Vitale, P	1
Du, J; Liu, H; Qin, J; Yang, Y; Yao, X	1
Behrens, F; Burkhardt, H; Koehm, M	1
Nagi Reddy, M; Rajanarendar, E; Rama Murthy, K; Reddy, RN; Reddy, YN; Surendar, P	1
Kiran, LH; Krishna, SR; Narasimha Reddy, AR; Rajanarendar, E; Raju, S; Reddy, MN; Reddy, YN	1
Abo-Salem, HM; El-Sawy, ER; Islam, IE; Mahmoud, K; Mandour, AH	1
Barsoum, J; Borella, C; Foley, KP; Jiang, J; Korbut, T; Li, H; Sang, J; Sonderfan, AJ; Wu, Y; Ye, J; Zhang, M; Zhang, X; Zhou, D	1
Dadmal, TL; Janaki Ramaiah, M; Kosurkar, UB; Kumbhare, RM; Pal-Bhadra, M; Pushpavalli, SN	1
Brumby, AM; Humbert, PO; Manning, SA; Parisot, JP; Richardson, HE; Schlosser, T; Street, IP; Willoughby, LF	1
Aszalos, A; Cardarelli, C; Forte, R; Gottesman, MM; Kozar, M; Liang, XJ; Taylor, B; Wang, PC; Yin, JJ; Zhou, JW	1
Aoki, J; Arai, H; Chun, J; Fukaya, M; Hama, K; Kishi, Y; Ohta, H; Sakai, T; Suzuki, R; Watanabe, M; Yamori, T	1
Vanchieri, C	1
Han, DC; Koh, S; Kwon, BM; Lee, MY; Lee, S; Paik, YK; Shin, DS; Shin, KD; Son, KH	1
Bichat, F; Fujiwara, Y; Guilbaud, N; Hasegawa, K; Isae, T; Kubo, K; Miura, T; Nakamura, K; Shibuya, M; Suzuki, R; Taguchi, E; Takahashi, K; Yamamoto, A	1
Chen, J; Fang, X; Gibson, SB; Graham, BA; Hu, X; Ishdorj, G; Johnston, JB	1
Weber, G	1
Alonso, MT; Leyland-Jones, B; O'Dwyer, PJ	1
Belt, RJ; Haas, CD; Hoogstraten, B; Joseph, U; Taylor, S	1
Kjaer, M; Nielsen, H	1
Bruno, S; McGovren, JP; Neil, GL; Penta, J; Poster, DS	1
Kufe, DW; McGovren, JP; Schade, D; Weiss, GR	1
Souba, WW	1
Baruchel, S; Bell, B; Bernstein, M; Devine, S; Dubowy, R; Grier, H; Kretschmar, C; Langevin, AM; Vietti, T; Whitehead, VM	1
Daniels, DL; Debnath, ML; Hall, IH; Izydore, RA; Muhammad, RA; Tse, E; Woodard, T; Zhou, X	1
Brown, T; Hidalgo, M; Kuhn, JG; MacGovren, JP; Rodriguez, G; Rowinsky, EK; Von Hoff, DD; Weiss, G	1
Hudes, G	1
Baker, SD; Cropp, G; Drengler, R; Eckardt, JR; Eckhardt, SG; Hammond, L; Hannah, AL; Kraynak, MA; Kuhn, JG; Moczygemba, J; Rizzo, J; Rowinsky, EK; Smith, L; Sweeney, KR; Thurman, A; Villalona-Calero, MA; Von Hoff, DD; Weiss, G	1
Doi, H; Komatsu, H; Nishihira, T; Satomi, S	1
Alberti, D; Bruggink, J; Earhart, RH; Fischer, PH; Hamilton, RD; Koeller, JM; Simon, K; Tormey, DC; Tutsch, K; Willson, JK	1

Reviews

12 review(s) available for isoxazoles and Neoplasms

Article	Year
Combination of Anti-Cancer Drugs with Molecular Chaperone Inhibitors. International journal of molecular sciences, 2019, Oct-24, Volume: 20, Issue:21 Topics: Antineoplastic Agents; Drug Therapy, Combination; Heat-Shock Proteins; HSP70 Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Molecular Chaperones; Neoplasms; Oligonucleotides; Resorcinols	2019
Discovery of ATR kinase inhibitor berzosertib (VX-970, M6620): Clinical candidate for cancer therapy. Pharmacology & therapeutics, 2020, Volume: 210 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated Proteins; Drug Discovery; Drug Synergism; Humans; Isoxazoles; Molecular Targeted Therapy; Neoplasms; Protein Kinase Inhibitors; Pyrazines; Signal Transduction; Sulfones; Treatment Outcome	2020
Leflunomide: A promising drug with good antitumor potential. Biochemical and biophysical research communications, 2018, 02-05, Volume: 496, Issue:2 Topics: Angiogenesis Inhibitors; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Enzyme Inhibitors; Humans; Immunologic Factors; Isoxazoles; Leflunomide; Neoplasms; Neoplastic Stem Cells	2018
The recent progress of isoxazole in medicinal chemistry. Bioorganic & medicinal chemistry, 2018, 07-23, Volume: 26, Issue:12 Topics: Anti-Infective Agents; Antineoplastic Agents; Bacteria; Cell Survival; Chemistry, Pharmaceutical; Fungi; Humans; Isoxazoles; Neoplasms; RNA Viruses	2018
Targeting ATR in cancer. Nature reviews. Cancer, 2018, Volume: 18, Issue:9 Topics: Ataxia Telangiectasia Mutated Proteins; DNA Damage; Drug Development; Genomic Instability; Humans; Indoles; Isoxazoles; Molecular Targeted Therapy; Morpholines; Neoplasms; Nitroso Compounds; Oxazines; Protein Kinase Inhibitors; Pyrazines; Pyrimidines; Quinolines; Sulfonamides; Sulfoxides	2018
Drugging ATR: progress in the development of specific inhibitors for the treatment of cancer. Future medicinal chemistry, 2015, Volume: 7, Issue:7 Topics: Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; DNA Damage; Humans; Isoxazoles; Molecular Conformation; Neoplasms; Pyrazines	2015
Selective COX-1 inhibition: A therapeutic target to be reconsidered. Current medicinal chemistry, 2010, Volume: 17, Issue:32 Topics: Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 1; Cyclooxygenase Inhibitors; Endothelial Cells; Female; Humans; Isoxazoles; Neoplasms; Nervous System Diseases; Obstetric Labor, Premature; Pain; Pregnancy	2010
Update 2011: leflunomide in rheumatoid arthritis - strengths and weaknesses. Current opinion in rheumatology, 2011, Volume: 23, Issue:3 Topics: Antibodies, Monoclonal, Murine-Derived; Antirheumatic Agents; Arthritis, Juvenile; Arthritis, Rheumatoid; Clinical Trials as Topic; Drug Therapy, Combination; Intercellular Adhesion Molecule-1; Isoxazoles; Leflunomide; Liver; Lung Diseases; Lymphocyte Function-Associated Antigen-1; Methotrexate; Neoplasms; Pharmacogenetics; Rituximab; Tumor Necrosis Factor-alpha	2011
Biochemical strategy of cancer cells and the design of chemotherapy: G. H. A. Clowes Memorial Lecture. Cancer research, 1983, Volume: 43, Issue:8 Topics: Adenosine Monophosphate; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Transformation, Neoplastic; Deoxyribonucleotides; Gene Expression Regulation; Gluconeogenesis; Guanosine Monophosphate; Humans; Inosine Monophosphate; Isoxazoles; Kidney Neoplasms; Liver Neoplasms; Liver Regeneration; Models, Biological; Neoplasms; Purines; Pyrimidines; Ribonucleotides	1983
Acivicin. An antitumor antibiotic. Cancer clinical trials, 1981,Fall, Volume: 4, Issue:3 Topics: Animals; Antibiotics, Antineoplastic; Glycine; Humans; Isoxazoles; Neoplasms; Neoplasms, Experimental; Oxazoles	1981
Glutamine and cancer. Annals of surgery, 1993, Volume: 218, Issue:6 Topics: Antimetabolites, Antineoplastic; Cell Division; Diazooxonorleucine; Glutamine; Humans; Intestinal Mucosa; Intestines; Isoxazoles; Lymphocytes; Muscles; Neoplasms; Parenteral Nutrition, Total; Randomized Controlled Trials as Topic	1993
[Anti-cancer therapy with amino acid imbalance]. Nihon rinsho. Japanese journal of clinical medicine, 2001, Volume: 59 Suppl 5 Topics: Amino Acids; Antimetabolites, Antineoplastic; Arginine; Asparagine; Glutamine; Humans; Isoxazoles; Methionine; Neoplasms; Valine	2001

Trials

7 trial(s) available for isoxazoles and Neoplasms

Article	Year
Population pharmacokinetics of ATR inhibitor berzosertib in phase I studies for different cancer types. Cancer chemotherapy and pharmacology, 2021, Volume: 87, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated Proteins; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Inhibitory Concentration 50; Isoxazoles; Male; Middle Aged; Models, Biological; Neoplasms; Protein Kinase Inhibitors; Pyrazines	2021
First-in-human phase I dose-escalation study of the HSP90 inhibitor AUY922 in patients with advanced solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Jul-01, Volume: 19, Issue:13 Topics: Adult; Aged; Antineoplastic Agents; Female; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Male; Middle Aged; Neoplasm Staging; Neoplasms; Resorcinols; Treatment Outcome	2013
Phase I dose-escalation study of the HSP90 inhibitor AUY922 in Japanese patients with advanced solid tumors. Cancer chemotherapy and pharmacology, 2014, Volume: 74, Issue:3 Topics: Antineoplastic Agents; Asian People; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Neoplasms; Resorcinols; Treatment Outcome	2014
A Phase I Study of the Hsp90 Inhibitor AUY922 plus Capecitabine for the Treatment of Patients with Advanced Solid Tumors. Cancer investigation, 2015, Volume: 33, Issue:10 Topics: Adult; Aged; Capecitabine; Female; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Male; Middle Aged; Neoplasms; Resorcinols	2015
A phase I study of acivicin in refractory pediatric solid tumors. A Pediatric Oncology Group study. Investigational new drugs, 1995, Volume: 13, Issue:3 Topics: Adolescent; Antimetabolites, Antineoplastic; Child; Child, Preschool; Drug Resistance, Neoplasm; Enzyme Inhibitors; gamma-Glutamyltransferase; Humans; Injections, Intravenous; Isoxazoles; Neoplasms; Tumor Cells, Cultured	1995
A Phase I and pharmacological study of the glutamine antagonist acivicin with the amino acid solution aminosyn in patients with advanced solid malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research, 1998, Volume: 4, Issue:11 Topics: Adult; Aged; Amino Acids; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Electrolytes; Female; Glucose; Glutamine; Humans; Isoxazoles; Male; Middle Aged; Neoplasms; Parenteral Nutrition Solutions; Solutions; Thrombocytopenia; Treatment Outcome	1998
Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:4 Topics: Adult; Aged; Chromatography, High Pressure Liquid; Female; Growth Inhibitors; Humans; Immunohistochemistry; Infusions, Intravenous; Isoxazoles; Leflunomide; Male; Middle Aged; Neoplasms; Receptor Protein-Tyrosine Kinases; Receptors, Platelet-Derived Growth Factor; Signal Transduction; Time Factors	1999

Other Studies

44 other study(ies) available for isoxazoles and Neoplasms

Article	Year
Development of VER-50589 analogs as novel Hsp90 inhibitors. Bioorganic & medicinal chemistry letters, 2023, Jul-15, Volume: 91 Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Neoplasms	2023
Parecoxib as an adjunct therapy for the treatment of refractory non-surgical cancer pain. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2020, Volume: 26, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Australia; Cancer Pain; Cohort Studies; Drug Therapy, Combination; Female; Humans; Isoxazoles; Male; Middle Aged; Neoplasms; Pain Measurement; Retrospective Studies; Young Adult	2020
1,3-Dipolar Cycloaddition, HPLC Enantioseparation, and Docking Studies of Saccharin/Isoxazole and Saccharin/Isoxazoline Derivatives as Selective Carbonic Anhydrase IX and XII Inhibitors. Journal of medicinal chemistry, 2020, 03-12, Volume: 63, Issue:5 Topics: Antigens, Neoplasm; Antineoplastic Agents; Carbonic Anhydrase Inhibitors; Carbonic Anhydrase IX; Carbonic Anhydrases; Cell Line; Cycloaddition Reaction; Humans; Isoxazoles; MCF-7 Cells; Molecular Docking Simulation; Neoplasms; Saccharin	2020
Rationally Designed Polypharmacology: α-Helix Mimetics as Dual Inhibitors of the Oncoproteins Mcl-1 and HDM2. ChemMedChem, 2020, 09-16, Volume: 15, Issue:18 Topics: Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Design; Humans; Isoxazoles; Molecular Structure; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasms; Protein Binding; Protein Conformation, alpha-Helical; Proto-Oncogene Proteins c-mdm2; Pyrazoles; Structure-Activity Relationship; Thiazoles	2020
Anti-cancer strategy targeting the energy metabolism of tumor cells surviving a low-nutrient acidic microenvironment. Molecular metabolism, 2020, Volume: 42 Topics: Acidosis; Antineoplastic Agents; Cell Hypoxia; Cell Line, Tumor; Cell Survival; Energy Metabolism; Gene Expression Regulation, Neoplastic; Glucose; Humans; Hydrazones; Isoxazoles; Mitochondria; Neoplasms; Tumor Microenvironment	2020
Targeting Akt as strategy to kill cancer cells using 3-substituted 5-anilinobenzo[c]isoxazolequinones: A preliminary study. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2018, Volume: 97 Topics: Adenosine Triphosphate; Antineoplastic Agents; Apoptosis; Caspase 3; Cell Line; Cell Line, Tumor; Fibroblasts; Glutathione; HSP90 Heat-Shock Proteins; Humans; Inhibitory Concentration 50; Isoxazoles; Neoplasms; Proto-Oncogene Proteins c-akt; Quinones; Structure-Activity Relationship	2018
COX‑2 inhibition in the endothelium induces glucose metabolism normalization and impairs tumor progression. Molecular medicine reports, 2018, Volume: 17, Issue:2 Topics: Animals; Antineoplastic Agents; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Disease Progression; Endothelial Cells; Female; Glucose; Glycolysis; Isoxazoles; Mice, Inbred C57BL; Neoplasms; Ovarian Neoplasms; Tumor Microenvironment; Vascular Endothelial Growth Factor A	2018
Simultaneous determination of parecoxib and its main metabolites valdecoxib and hydroxylated valdecoxib in mouse plasma with a sensitive LC-MS/MS method to elucidate the decreased drug metabolism of tumor bearing mice. Journal of pharmaceutical and biomedical analysis, 2018, Sep-05, Volume: 158 Topics: Animals; Cell Line, Tumor; Chromatography, High Pressure Liquid; Cyclooxygenase 2 Inhibitors; Cytochrome P-450 Enzyme System; Drug Monitoring; Female; Humans; Isoxazoles; Mice; Mice, Inbred BALB C; Neoplasms; Oxazoles; Prodrugs; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Sulfonamides; Tandem Mass Spectrometry; Xenograft Model Antitumor Assays	2018
Synthesis of Novel Diaziridinyl Quinone Isoxazole Hybrids and Evaluation of Their Anti-Cancer Activity as Potential Tubulin-Targeting Agents. Drug research, 2019, Volume: 69, Issue:7 Topics: Antineoplastic Agents; Azirines; Cell Line, Tumor; Chemistry Techniques, Synthetic; Drug Screening Assays, Antitumor; HEK293 Cells; Humans; Inhibitory Concentration 50; Isoxazoles; Neoplasms; Quinones; Toxicity Tests; Tubulin; Tubulin Modulators	2019
Glyphosate and AMPA inhibit cancer cell growth through inhibiting intracellular glycine synthesis. Drug design, development and therapy, 2013, Volume: 7 Topics: Apoptosis; Cell Cycle; Cell Line; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Epithelial Cells; Female; Glycine; Glyphosate; Humans; Isoxazoles; Male; Neoplasms; Organophosphonates; Prostate; Tetrazoles; Up-Regulation	2013
Drug analogs of COX-2 selective inhibitors lumiracoxib and valdecoxib derived from in silico search and optimization. Anti-inflammatory & anti-allergy agents in medicinal chemistry, 2014, Volume: 13, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Computer Simulation; Cyclooxygenase 2 Inhibitors; Diclofenac; Drug Design; Humans; Isoxazoles; Models, Molecular; Neoplasms; Pain; Sulfonamides	2014
Targeting LIM kinase in cancer and neurofibromatosis. Cell cycle (Georgetown, Tex.), 2014, Volume: 13, Issue:9 Topics: Animals; Antineoplastic Agents; Benzamides; Humans; Isoxazoles; Lim Kinases; Mice; Neoplasms; Neurofibromatosis 1	2014
Small molecule inhibitors targeting activator protein 1 (AP-1). Journal of medicinal chemistry, 2014, Aug-28, Volume: 57, Issue:16 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Benzophenones; Biological Products; Humans; Inflammation; Isoxazoles; Maleimides; Molecular Targeted Therapy; Neoplasms; Organic Chemicals; Quinazolines; Signal Transduction; Small Molecule Libraries; Transcription Factor AP-1; Transcription Factors	2014
An in vivo antilymphatic screen in zebrafish identifies novel inhibitors of mammalian lymphangiogenesis and lymphatic-mediated metastasis. Molecular cancer therapeutics, 2014, Volume: 13, Issue:10 Topics: Animals; Antineoplastic Agents; Cinnarizine; Endothelial Cells; Female; Flunarizine; Humans; Isoxazoles; Kaempferols; Leflunomide; Lymph Nodes; Lymphangiogenesis; Lymphatic Metastasis; Mice; Mice, Inbred C57BL; Neoplasms; Random Allocation; Receptor Protein-Tyrosine Kinases; Zebrafish	2014
Sensitizing tumor cells to radiation by targeting the heat shock response. Cancer letters, 2015, May-01, Volume: 360, Issue:2 Topics: Cell Line, Tumor; Cell Movement; DNA-Binding Proteins; Fibroblasts; Heat Shock Transcription Factors; Heat-Shock Response; HSP70 Heat-Shock Proteins; Humans; Isoxazoles; Neoplasms; Radiation Tolerance; Radiation-Sensitizing Agents; Resorcinols; Transcription Factors	2015
Bioactive secondary metabolites from the Red Sea marine Verongid sponge Suberea species. Marine drugs, 2015, Mar-24, Volume: 13, Issue:4 Topics: Alkaloids; Animals; Antineoplastic Agents; Benzofurans; Bromobenzenes; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Discovery; Egypt; Humans; Hydrocarbons, Brominated; Hydroquinones; Isoxazoles; Magnetic Resonance Spectroscopy; Molecular Structure; Neoplasms; Oceans and Seas; Porifera; Saudi Arabia; Secondary Metabolism; Spectrometry, Mass, Electrospray Ionization; Spiro Compounds; Stereoisomerism	2015
Small molecule/ML327 mediated transcriptional de-repression of E-cadherin and inhibition of epithelial-to-mesenchymal transition. Oncotarget, 2015, Sep-08, Volume: 6, Issue:26 Topics: Animals; Cadherins; Cell Line, Tumor; Chick Embryo; Colorectal Neoplasms; Epithelial-Mesenchymal Transition; Female; Humans; Isoxazoles; Lung Neoplasms; Mammary Neoplasms, Experimental; Mice; Neoplasm Invasiveness; Neoplasms; Niacinamide; Small Molecule Libraries; Transcription, Genetic	2015
Identification of a novel 5-amino-3-(5-cyclopropylisoxazol-3-yl)-1-isopropyl-1H-pyrazole-4-carboxamide as a specific RET kinase inhibitor. European journal of medicinal chemistry, 2017, Jan-05, Volume: 125 Topics: Animals; Cell Line, Tumor; Cell Proliferation; Humans; Isoxazoles; Mice; Models, Molecular; Mutation; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Pyrazoles	2017
Synthesis of hetero annulated isoxazolo-, pyrido- and pyrimido carbazoles: Screened for in vitro antitumor activity and structure activity relationships, a novel 2-amino-4-(3'-bromo-4'-methoxyphenyl)-8-chloro-11H-pyrimido[4,5-a]carbazole as an antitumor a European journal of medicinal chemistry, 2017, Mar-10, Volume: 128 Topics: Antineoplastic Agents; Carbazoles; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Isoxazoles; Molecular Structure; Neoplasms; Pyridones; Pyrimidines; Pyrimidinones; Spectroscopy, Fourier Transform Infrared; Structure-Activity Relationship; Tumor Cells, Cultured	2017
Small molecule inhibitors block Gas6-inducible TAM activation and tumorigenicity. Scientific reports, 2017, 03-08, Volume: 7 Topics: Animals; Axl Receptor Tyrosine Kinase; Binding Sites; Body Weight; c-Mer Tyrosine Kinase; Carcinogenesis; Cell Line, Tumor; Humans; Intercellular Signaling Peptides and Proteins; Isoxazoles; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasms; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Transplantation, Heterologous	2017
Evaluation of the Hsp90 inhibitor NVP-AUY922 in multicellular tumour spheroids with respect to effects on growth and PET tracer uptake. Nuclear medicine and biology, 2009, Volume: 36, Issue:3 Topics: Animals; Biological Transport; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Neoplasms; Positron-Emission Tomography; Radioactive Tracers; Resorcinols; Spheroids, Cellular; Time Factors	2009
89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2010, Volume: 51, Issue:5 Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Cisplatin; Drug Resistance, Neoplasm; Female; HSP90 Heat-Shock Proteins; Immunohistochemistry; Isoxazoles; Ki-67 Antigen; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neoplasms; Neovascularization, Pathologic; Ovarian Neoplasms; Radioisotopes; Radionuclide Imaging; Radiopharmaceuticals; Resorcinols; Tissue Distribution; Vascular Endothelial Growth Factor A; Zirconium	2010
Synthesis and antitumor activity of 2,5-bis(3'-indolyl)-furans and 3,5-bis(3'-indolyl)-isoxazoles, nortopsentin analogues. Bioorganic & medicinal chemistry, 2010, Jun-15, Volume: 18, Issue:12 Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Screening Assays, Antitumor; Furans; Humans; Indoles; Isoxazoles; Neoplasms	2010
Novel HSP90 inhibitors, NVP-AUY922 and NVP-BEP800, radiosensitise tumour cells through cell-cycle impairment, increased DNA damage and repair protraction. British journal of cancer, 2010, May-25, Volume: 102, Issue:11 Topics: Benzoquinones; Cell Cycle; Cell Line, Tumor; Cell Survival; DNA Damage; DNA Repair; DNA, Neoplasm; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Down-Regulation; Drug Evaluation, Preclinical; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Lactams, Macrocyclic; Neoplasms; Pyrimidines; Radiation Tolerance; Radiation-Sensitizing Agents; Resorcinols; Up-Regulation	2010
A combined molecular modeling study on a series of pyrazole/isoxazole based human Hsp90α inhibitors. Journal of molecular modeling, 2011, Volume: 17, Issue:12 Topics: Binding Sites; Computer Simulation; HSP90 Heat-Shock Proteins; Humans; Hydrogen Bonding; Hydrophobic and Hydrophilic Interactions; Isoxazoles; Models, Chemical; Models, Molecular; Molecular Conformation; Neoplasms; Protein Binding; Pyrazoles; Quantitative Structure-Activity Relationship; Thermodynamics	2011
Synthesis and in vitro and in vivo anticancer activity of novel phenylmethylene bis-isoxazolo[4,5-b]azepines. Bioorganic & medicinal chemistry letters, 2012, Jan-01, Volume: 22, Issue:1 Topics: Animals; Antineoplastic Agents; Azepines; Cell Line, Tumor; Chemistry, Pharmaceutical; Cisplatin; Drug Design; Drug Screening Assays, Antitumor; Humans; In Vitro Techniques; Inhibitory Concentration 50; Isoxazoles; Magnetic Resonance Spectroscopy; Mass Spectrometry; Methanol; Mice; Models, Chemical; Neoplasms; Spectrophotometry, Infrared; Tetrazolium Salts; Thiazoles	2012
Multi-component synthesis and in vitro and in vivo anticancer activity of novel arylmethylene bis-isoxazolo[4,5-b]pyridine-N-oxides. European journal of medicinal chemistry, 2012, Volume: 50 Topics: Animals; Antineoplastic Agents; Cyclic N-Oxides; Drug Screening Assays, Antitumor; Female; Humans; In Vitro Techniques; Isoxazoles; Mice; Molecular Structure; Neoplasms; Structure-Activity Relationship; Tumor Cells, Cultured	2012
Synthesis, antimicrobial and anti-cancer activities of some new N-ethyl, N-benzyl and N-benzoyl-3-indolyl heterocycles. Acta pharmaceutica (Zagreb, Croatia), 2012, Volume: 62, Issue:2 Topics: Anti-Infective Agents; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chalcones; Cyclohexanones; Disk Diffusion Antimicrobial Tests; Drug Design; Fungi; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Indoles; Inhibitory Concentration 50; Isoxazoles; Neoplasms; Pyrazoles; Pyrimidines; Structure-Activity Relationship	2012
The vascular disrupting agent STA-9584 exhibits potent antitumor activity by selectively targeting microvasculature at both the center and periphery of tumors. The Journal of pharmacology and experimental therapeutics, 2012, Volume: 343, Issue:2 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Bibenzyls; Cell Survival; Dogs; Female; Heart; Hemodynamics; Human Umbilical Vein Endothelial Cells; Humans; In Vitro Techniques; Isoxazoles; Male; Mice; Mice, Inbred BALB C; Mice, SCID; Microcirculation; Neoplasms; Neovascularization, Pathologic; Phenylalanine; Rabbits; Regional Blood Flow; Tubulin Modulators; Xenograft Model Antitumor Assays	2012
Synthesis and biological evaluation of novel triazoles and isoxazoles linked 2-phenyl benzothiazole as potential anticancer agents. Bioorganic & medicinal chemistry letters, 2012, Sep-01, Volume: 22, Issue:17 Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Isoxazoles; Neoplasms; Structure-Activity Relationship; Thiazoles; Triazoles	2012
An in vivo large-scale chemical screening platform using Drosophila for anti-cancer drug discovery. Disease models & mechanisms, 2013, Volume: 6, Issue:2 Topics: Animals; Antineoplastic Agents; Benzamides; Biological Availability; Cell Proliferation; Cytidine Triphosphate; Diphenylamine; Drosophila melanogaster; Drug Screening Assays, Antitumor; Glutamine; Isoxazoles; Neoplasms; Pharmacogenetics; Pilot Projects	2013
Changes in biophysical parameters of plasma membranes influence cisplatin resistance of sensitive and resistant epidermal carcinoma cells. Experimental cell research, 2004, Feb-15, Volume: 293, Issue:2 Topics: Carcinoma; Cell Division; Cell Line, Tumor; Cell Membrane; Cisplatin; Clone Cells; Cyclic N-Oxides; Drug Resistance, Neoplasm; Fatty Acids; HeLa Cells; Humans; Isoxazoles; Membrane Fluidity; Membrane Lipids; Membrane Potentials; Membrane Proteins; Neoplasms; Potassium Channels; Pyrimidinones	2004
Lysophosphatidic acid and autotaxin stimulate cell motility of neoplastic and non-neoplastic cells through LPA1. The Journal of biological chemistry, 2004, Apr-23, Volume: 279, Issue:17 Topics: Animals; Calcium; Cell Line; Cell Line, Tumor; Cell Movement; Cells, Cultured; Chemotaxis; Dose-Response Relationship, Drug; Fibroblasts; Glucose-6-Phosphate Isomerase; Glycoproteins; Isoxazoles; Lysophospholipids; Mice; Mice, Knockout; Mice, Transgenic; Microscopy, Fluorescence; Models, Biological; Multienzyme Complexes; Neoplasms; Phosphodiesterase I; Phosphoric Diester Hydrolases; Platelet-Derived Growth Factor; Propionates; Pyrophosphatases; rac1 GTP-Binding Protein; Reverse Transcriptase Polymerase Chain Reaction; rhoA GTP-Binding Protein; Signal Transduction; Skin; Time Factors	2004
Researchers plan to continue to study COX-2 inhibitors in cancer treatment and prevention. Journal of the National Cancer Institute, 2005, Apr-20, Volume: 97, Issue:8 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Antineoplastic Agents; Celecoxib; Clinical Trials as Topic; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Humans; Incidence; Isoxazoles; Lactones; Membrane Proteins; Meta-Analysis as Topic; Myocardial Infarction; Neoplasms; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Sulfones; United States; United States Food and Drug Administration	2005
Blocking tumor cell migration and invasion with biphenyl isoxazole derivative KRIBB3, a synthetic molecule that inhibits Hsp27 phosphorylation. The Journal of biological chemistry, 2005, Dec-16, Volume: 280, Issue:50 Topics: Amino Acid Sequence; Anisoles; Antineoplastic Agents; Blotting, Western; Bromides; Cell Line, Tumor; Cell Membrane; Cell Movement; Chromatography, Affinity; Crk-Associated Substrate Protein; DNA, Complementary; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Enzyme Activation; Enzyme Inhibitors; Focal Adhesion Protein-Tyrosine Kinases; Heat-Shock Proteins; HSP27 Heat-Shock Proteins; Humans; Inhibitory Concentration 50; Intracellular Signaling Peptides and Proteins; Isoxazoles; Models, Chemical; Molecular Chaperones; Molecular Sequence Data; Neoplasm Invasiveness; Neoplasm Proteins; Neoplasms; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Binding; Protein Kinase C; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; RNA, Small Interfering; Time Factors; Transfection	2005
KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties. Cancer research, 2006, Sep-15, Volume: 66, Issue:18 Topics: Animals; Antineoplastic Agents; Capillary Permeability; Cell Line, Tumor; Endothelial Cells; Humans; Isoxazoles; Magnetic Resonance Imaging; Mice; Neoplasms; Neovascularization, Pathologic; NIH 3T3 Cells; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Random Allocation; Rats; Rats, Nude; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays	2006
Lysophosphatidic acid protects cancer cells from histone deacetylase (HDAC) inhibitor-induced apoptosis through activation of HDAC. The Journal of biological chemistry, 2008, Jun-13, Volume: 283, Issue:24 Topics: Apoptosis; Catalysis; Cell Membrane; Histone Deacetylase 2; Histone Deacetylase Inhibitors; Histone Deacetylases; Histones; Humans; Isoxazoles; Lymphocytes; Lysophospholipids; Models, Biological; Neoplasms; Permeability; Promoter Regions, Genetic; Propionates; Repressor Proteins	2008
Acivicin: a new glutamine antagonist in clinical trials. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1984, Volume: 2, Issue:9 Topics: Animals; Antibiotics, Antineoplastic; Antimetabolites; Dose-Response Relationship, Drug; Drug Evaluation; Female; Glutamine; Half-Life; Humans; Isoxazoles; Kinetics; Leukemia, Experimental; Liver Neoplasms, Experimental; Macaca mulatta; Male; Mice; Neoplasms; Oxazoles; Purines; Pyrimidines; Sarcoma, Experimental	1984
Phase I evaluation of AT-125 single dose every three weeks. Investigational new drugs, 1984, Volume: 2, Issue:3 Topics: Adult; Aged; Antibiotics, Antineoplastic; Central Nervous System; Drug Administration Schedule; Drug Evaluation; Glutamine; Humans; Isoxazoles; Middle Aged; Neoplasms; Oxazoles	1984
The analgesic effect of the GABA-agonist THIP in patients with chronic pain of malignant origin. A phase-1-2 study. British journal of clinical pharmacology, 1983, Volume: 16, Issue:5 Topics: Adult; Aged; Analgesics; Analysis of Variance; Chronic Disease; Drug Evaluation; Female; Humans; Isoxazoles; Male; Middle Aged; Neoplasms; Oxazoles; Pain	1983
Phase I and pharmacological study of acivicin by 24-hour continuous infusion. Cancer research, 1982, Volume: 42, Issue:9 Topics: Antimetabolites; Digestive System; Drug Evaluation; Humans; Infusions, Parenteral; Isoxazoles; Kinetics; Neoplasms; Nervous System; Oxazoles	1982
Synthesis and cytotoxic action of 3,5-isoxazolidinediones and 2-isoxazolin-5-ones in murine and human tumors. Archiv der Pharmazie, 1997, Volume: 330, Issue:3 Topics: Animals; Antineoplastic Agents; Female; Humans; Isoxazoles; Mice; Molecular Structure; Neoplasms; Neoplasms, Experimental; Tumor Cells, Cultured	1997
Signaling inhibitors in the clinic: new agents and new challenges. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:4 Topics: Clinical Trials, Phase I as Topic; Growth Inhibitors; Humans; Isoxazoles; Leflunomide; Neoplasms; Phosphorylation; Receptor Protein-Tyrosine Kinases; Signal Transduction	1999
Phase I clinical trial of a combination of dipyridamole and acivicin based upon inhibition of nucleoside salvage. Cancer research, 1988, Oct-01, Volume: 48, Issue:19 Topics: Antineoplastic Combined Chemotherapy Protocols; Chromatography, High Pressure Liquid; Dipyridamole; Drug Evaluation; Humans; Isoxazoles; Leukocyte Count; Metabolic Clearance Rate; Neoplasms; Nucleosides	1988